Commercialisation of CAR T-cell therapies: business model spectrum
Drug Discov Today
.
2017 Jan;22(1):1-4.
doi: 10.1016/j.drudis.2016.11.010.
Epub 2016 Nov 16.
Authors
Nafees N Malik
1
,
Matthew B Durdy
2
Affiliations
1
Asklepian Consulting, International House, 24 Holborn Viaduct, London EC1A 2BN, United Kingdom. Electronic address: nmalik@asklepianconsulting.com.
2
Cell and Gene Therapy Catapult, 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom.
PMID:
27866009
DOI:
10.1016/j.drudis.2016.11.010
No abstract available
Publication types
Editorial
MeSH terms
Humans
Immunotherapy / economics*
Models, Economic*
Neoplasms / immunology*
Receptors, Antigen, T-Cell / immunology*
Substances
Receptors, Antigen, T-Cell